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A variant in CDKAL1 influences insulin response and risk 
of type 2 diabetes
Valgerdur Steinthorsdottir1,15, Gudmar Thorleifsson1,15, Inga Reynisdottir1, Rafn Benediktsson2,3, 
Thorbjorg Jonsdottir1, G Bragi Walters1, Unnur Styrkarsdottir1, Solveig Gretarsdottir1, Valur Emilsson1, 
Shyamali Ghosh1, Adam Baker1, Steinunn Snorradottir1, Hjordis Bjarnason1, Maggie C Y Ng4, Torben Hansen5, 
Yu Bagger6, Robert L Wilensky7, Muredach P Reilly7, Adebowale Adeyemo8, Yuanxiu Chen8, Jie Zhou8, 
Vilmundur Gudnason3, Guanjie Chen8, Hanxia Huang8, Kerrie Lashley8, Ayo Doumatey8, Wing-Yee So4, 
Ronald C Y Ma4, Gitte Andersen5, Knut Borch-Johnsen5,9,10, Torben Jorgensen10, Jana V van Vliet-Ostaptchouk11, 
Marten H Hofker11,12, Cisca Wijmenga13,14, Claus Christiansen6, Daniel J Rader7, Charles Rotimi8, Mark Gurney1, 
Juliana C N Chan4, Oluf Pedersen5,9,Gunnar Sigurdsson2,3, Jeffrey R Gulcher1, Unnur Thorsteinsdottir1, 
Augustine Kong1 & Kari Stefansson1
We conducted a genome-wide association study for type 2 
diabetes (T2D) in Icelandic cases and controls, and we found 
that a previously described variant in the transcription factor 
7-like 2 gene (TCF7L2) gene conferred the most significant risk. 
In addition to confirming two recently identified risk variants1, 
we identified a variant in the CDKAL1 gene that was associated 
with T2D in individuals of European ancestry (allele-specific 
odds ratio (OR) = 1.20 (95% confidence interval, 1.13–1.27), 
P = 7.7 × 10−9) and individuals from Hong Kong of Han 
Chinese ancestry (OR = 1.25 (1.11–1.40), P = 0.00018). 
The genotype OR of this variant suggested that the effect 
was substantially stronger in homozygous carriers than 
in heterozygous carriers. The ORs for homozygotes were 
1.50 (1.31–1.72) and 1.55 (1.23–1.95) in the European 
and Hong Kong groups, respectively. The insulin response 
for homozygotes was approximately 20% lower than for 
heterozygotes or noncarriers, suggesting that this variant 
confers risk of T2D through reduced insulin secretion.
We recently described a variant in TCF7L2 associated with T2D2,3. To 
look for additional genetic variants that increase the risk of develop-
ing T2D, we performed a genome-wide association study on Icelandic 
individuals with T2D using the Illumina HumanHap300 chip. We tested 
313,179 SNPs individually for association with T2D in a sample of 1,399 
individuals with T2D and 5,275 controls. We tested an additional 339,846 
two-marker haplotypes identified as efficient surrogates (r2 > 0.8) for 
a set of SNPs that were not included on the Hap300 chip but that were 
typed in the HapMap project4. In addition to analyzing the entire group 
of individuals with T2D, separately we tested 700 non-obese individuals 
with T2D and 531 obese individuals with T2D for association. Overall, 
we performed a total of 1,959,075 (653,025 variants × 3 phenotypes) 
tests. The results were adjusted for relatedness between individuals and 
potential population stratification by genomic control5 (see Methods). 
A previously identified SNP, rs7903146, in TCF7L2 gave the most signifi-
cant results, with OR = 1.38 and P = 1.82 × 10−10 in all individuals with 
T2D. Although no other SNP or haplotype was significant after adjust-
ment for the number of tests performed, we observed more borderline-
significant signals than expected by chance alone (Supplementary Fig. 1
online). A comprehensive follow-up strategy would require genotyping 
a large number of SNPs6, so we decided to pursue the top signals quickly 
in a fast-tracking effort.
For each phenotype tested, we selected all single SNPs and two-marker 
haplotypes with P < 0.00005 for replication in a case-control sample 
from Denmark (Denmark B). After eliminating redundant markers, 
we selected a total of 46 SNPs for replication (Supplementary Table 1
online). In addition, we included the five most significant nonsynony-
mous SNPs present on the Illumina Hap300 chip. Of these 51 SNPs, we 
successfully genotyped 47 in 1,110 Danish T2D cases and 2,272 controls. 
In the Danish group of all individuals with T2D, SNPs rs7756992 and 
rs13266634 stood out and were significantly replicated (P = 0.00013 and 
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OR = 1.24 and P = 0.0012 and OR = 1.20, respectively; Supplementary 
Table 2 online), compared with P = 0.00021 and OR = 1.23 and P =
0.000061 and OR = 1.19, respectively, in the initial Icelandic study. All 
of the other SNPs genotyped had P > 0.01 in the Danish group, and we 
chose not to pursue them further. The first SNP, rs7756992, is located 
in intron 5 of the CDK5 regulatory subunit associated protein 1-like 
1 (CDKAL1) gene on 6p22.3. It resides in a large LD block of 201.7 kb 
that includes exons 1–5 of the CDKAL1 gene and the minimal promoter 
region but no other known genes (Fig. 1). The second SNP, rs13266634, 
is a nonsynonymous SNP causing an arginine to tryptophan change at 
position 325 in the last exon of the solute carrier family 30 (zinc trans-
porter), member 8 (SLC30A8) gene on 8q24. SLC30A8 is specific to the 
pancreas and is expressed in beta cells, where it facilitates accumulation 
of zinc from the cytoplasm into intracellular vesicles7. The risk allele of 
rs13266634 on 8q24 has recently been found to confer risk of T2D in 
a genome-wide association study of French individuals with T2D and 
controls1. Of other significantly associated SNPs in that study, we also 
replicated, in the initial Icelandic samples, association with two SNPs 
close to the HHEX gene (Supplementary Table 3 online). However, in 
our samples, we did not replicate with significance the reported asso-
ciations to markers in the LOC387761 and EXT2 genes also described 
in that study.
We typed rs7756992 and rs13266634 in three other T2D case-con-
trol groups of European ancestry from Denmark (Denmark A), the 
Netherlands and Philadelphia as well as in case-control groups from 
Hong Kong and West Africa. Furthermore, we expanded the size of the 
Denmark B study group mostly by increasing the number of genotyped 
controls. The association of the G allele of rs7756992 was replicated 
with significance in the Hong Kong case-control group (OR = 1.25; P =
0.00018; Table 1). Association in other study groups was not individu-
ally significant, but all were in the same direction. Because some of the 
replication groups are not very large individually, the study should be 
considered as a whole in order to meaningfully interpret the results. 
Specifically, the observed association from combining all five case-
control groups of European ancestry gave an OR of 1.20 with a cor-
responding P value of 7.7 × 10−9 (Table 1). Given that approximately 
2 million tests were performed in the initial genome scan, this associa-
tion remained significant with Bonferroni adjustment6. Moreover, the 
Chinese data provided further support for the association. Even when 
combined with the West African data, which did not show a significant 
effect, it yielded a P value of 0.0050. Attempts at refining the association 
observed with rs7756992 by genotyping additional markers that cor-
relate with the original signal in the HapMap CEPH (CEU) data set did 
not yield more significant results (Supplementary Table 4 online). As 
we expected, the observed linkage disequilibrium was considerably lower 
for the West African population than for the Icelandic and Hong Kong 
groups (Supplementary Table 4). Further work is needed to determine 
if an associated variant with a higher OR than observed for rs7756992 
can be identified in the West African group. In total, we genotyped 61 
SNPs (of which 35 were on the Hap300 chip) in the LD block containing 
rs7756992 in the Icelandic case-control group (Supplementary Table 
5 online). After we adjusted for the observed association of rs7756992, 
Table 1 Association results for rs7756992 and rs13266634 in five T2D case-control groups of European ancestry and in case-control 
groups from Hong Kong and West Africa
Controls Affected individuals
Frq AA/Aa/aab Frq AA/Aa/aab OR (95% c.i.) P value
Iceland (1,399/ 5,275)
 rs7756992 (G) 0.232 3,107/1,887/277 0.270 751/539/108 1.23 (1.10–1.37) 0.00021
 rs13266634 (C) 0.646 700/2,339/2,236 0.685 143/596/660 1.19 (1.08–1.31) 0.0006
Denmark A (263/597)
 rs7756992 (G) 0.297 292/255/50 0.331 111/99/30 1.17 (0.93–1.47) 0.18
 rs13266634 (C) 0.686 62/242/279 0.672 35/99/124 0.94 (0.75–1.17) 0.58
Denmark B (1,359/4,825)
 rs7756992 (G) 0.279 2,503/1,884/394 0.320 624/564/144 1.21 (1.10–1.33) 0.000054
 rs13266634 (C) 0.673 555/1,997/2,204 0.692 128/566/639 1.09 (0.99–1.19) 0.073
Philadelphia (447/950)
 rs7756992 (G) 0.262 492/331/68 0.295 216/174/40 1.18 (0.98–1.42) 0.073
 rs13266634 (C) 0.678 85/377/387 0.760 29/145/249 1.51 (1.25–1.81) 1.5 × 10−5
The Netherlands (368/915)
 rs7756992 (G) 0.270 475/359/63 0.280 186/138/30 1.05 (0.86–1.29) 0.64
 rs13266634 (C) 0.717 80/349/469 0.736 28/136/199 1.10 (0.91–1.33) 0.33
European ancestry combineda (3,836/12,562)
 rs7756992 (G) 0.258 0.295 1.20 (1.13–1.27) 7.7 × 10−9
 rs13266634 (C) 0.666 0.700 1.15 (1.08–1.22) 3.3 × 10−6
Hong Kong (1,457/986)
 rs7756992 (G) 0.462 293/446/220 0.517 351/681/400 1.25 (1.11–1.40) 0.00018
 rs13266634 (C) 0.523 214/497/259 0.566 276/686/464 1.19 (1.06–1.33) 0.0035
West Africaa (865/1,106)
 rs7756992 (G) 0.612 160/499/397 0.625 137/349/344 1.02 (0.92–1.14) 0.72
 rs13266634 (C) 0.962 4/74/1004 0.971 2/45/804 1.26 (0.88–1.81) 0.21
Numbers in parentheses next to population names represent the number of individuals with T2D and controls, respectively. Also shown are the allelic frequency (Frq) and genotype counts in the 
affected and control individuals, the allelic OR with 95% confidence intervals (c.i.) and two-sided P values based on the multiplicative model.
aFor the combined European ancestry groups and the five West African groups, ORs and P values were combined using a Mantel-Haenszel model, and frequency in affected individuals and 
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none of the other SNPs were significantly associated with T2D. As was 
the case for rs7756992, the association with T2D for allele C of the non-
synonymous SNP rs13266634 was replicated with significance in two of 
the five additional groups (from Philadelphia and Hong Kong) (Table 1). 
Even though the OR for Denmark B decreased with the larger sample 
size, and the estimated effect was in the opposite direction (only slightly, 
and nonsignificantly) for Denmark A, the combined results from all 
study groups of European ancestry yielded a P value of 3.3 × 10−6 and 
an OR of 1.15 (Table 1).
In the Icelandic study, the observed association to rs7756992 was 
greater in non-obese individuals with T2D (OR = 1.37 (1.20–1.57); 
P = 9.0 × 10−6) than in the group of all individuals with T2D (OR = 
1.23 (1.10–1.37); P = 0.00021) (Supplementary Table 1 and Table 1). 
We also observed a higher OR in non-obese individuals than in obese 
individuals with T2D for this variant in the other populations studied. 
For the combined populations of European origin, the OR was 1.24 
(1.15–1.33) with P = 3.0 × 10−8 for the non-obese individuals with T2D 
compared with OR = 1.14 (1.04–1.25) and P = 0.004 for the obese group. 
We saw an even stronger effect in the Hong Kong non-obese T2D group 
(OR = 1.36 (1.19–1.56); P = 7.48 × 10−6) compared with the obese group 
(OR = 1.13 (0.98–1.30); P = 0.094). For the Hong Kong group, obesity 
was defined as a body mass index (BMI) ≥25. Furthermore, examination 
of the controls showed a very weak, but significant, negative correlation 
of the variant with BMI, a result that needs further confirmation. Most 
notably, the combined results indicate that this variant does not confer 
increased risk of T2D by increasing BMI.
We estimated genotype ORs for each of the two loci (Table 2). For 
the combined study of populations of European descent, the OR for 
heterozygotes for rs7756992 was 1.15 (1.06–1.24), which is smaller than 
that predicted by the multiplicative model, compared with an OR of 1.50 
(1.31–1.72) for homozygotes, which is larger than that predicted by the 
multiplicative model. We observed similar results for the Hong Kong 
samples (Table 2). Combining the European and Hong Kong data, we 
were able to reject the multiplicative model (P = 0.011). A multiplica-
tive model for the genotype relative risk provided an adequate fit for 
rs13266634.
The function of the gene product of CDKAL1 is unknown. 
However, the protein product is similar to another protein, 
CDK5 regulatory subunit–associated protein 1 (encoded by 
CDK5RAP1). CDK5RAP1 is expressed in neuronal tissues, 
where it inhibits cyclin-dependent kinase 5 (CDK5) activity 
by binding to the CDK5 regulatory subunit p35 (ref. 8). In 
pancreatic beta cells, CDK5 has been shown to have a role in 
the loss of beta cell function under glucotoxic conditions9. 
Furthermore, inhibition of the CDK5/p35 complex prevents 
a decrease of insulin gene expression that results from gluco-
toxicity10. It is tempting to speculate that CDKAL1 may have a 
role in the inhibition of the CDK5/p35 complex in pancreatic 
beta cells similar to that of CDK5RAP1 in neuronal tissue. 
Reduced expression of CDKAL1 or reduced inhibitory func-
tion thus could lead to an impaired response to glucotoxicity. 
Table 2 Genotype-specific OR for rs7756992 and rs13266634
Allelic OR Genotype ORa
(95% c.i.) 00 0X (95% c.i.) XX (95% c.i.) P b PAR
European ancestry
 rs7756992 (G) 1.20 (1.13–1.27) 1 1.15 (1.06–1.24) 1.50 (1.31–1.72) 0.089 0.061
 rs13266634 (C) 1.15 (1.08–1.22) 1 1.05 (0.93–1.19) 1.26 (1.10–1.43) 0.10 0.157
Hong Kong
 rs7756992 (G) 1.25 (1.11–1.40) 1 1.13 (0.97–1.31) 1.55 (1.23–1.95) 0.071 0.154
 rs13266634 (C) 1.19 (1.06–1.33) 1 1.13 (0.96–1.34) 1.40 (1.11–1.76) 0.43 0.148
PAR, population attributable risk.
aGenotype OR for heterozygous (0X) and homozygous carriers (XX) compared with noncarriers (00). bTest of the multiplicative model (the null hypotheses) versus the full model (that is, 
the model that puts no constraints on the genotype-specific risks). This test has one degree of freedom.







































Figure 1  Schematic view of the association of T2D with variants 
in the 6p22.3 region. (a) Pairwise correlation structure in a 1-Mb 
interval (20.5–21.5 Mb, NCBI build34) on chromosome 6. The 
upper plot includes pairwise D′ for 1,047 common SNPs (with 
MAF >5%) from the HapMap release 19 for the CEU population; 
the lower plot includes pairwise r2 values for the same set of 
SNPs. (b) Location of recombination hotspots in this interval 
based on the HapMap data set26. (c) Location of exons (vertical 
bars) of the two genes, E2F3 (blue) and CDKAL1 (red), that 
map to the interval. (d) Schematic view of the genome-wide 
association results in the interval for all T2D cases (black dots), 
non-obese T2D cases (blue dots) and obese T2D cases (red dots), 
respectively. –log P is plotted (where P is the adjusted P value) 
against the chromosomal location of the markers. All four panels 
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In this study, we found that CDKAL1 is expressed in the rat pancreatic 
beta cell line INS-1 (data not shown). Further studies are needed to 
determine if the effect of CDKAL1 on risk of T2D is exerted through 
this pathway.
Based on the predicted function of CDKAL1 and the known function 
of SLC30A8, we would expect both rs7756992 and rs13266634 to affect 
insulin secretion. To evaluate the effects of the two SNPs on insulin 
secretion, we analyzed the effect of genotype status on corrected insu-
lin response (CIR) in a set of individuals from the Inter99 study (part 
of Denmark B) that had undergone an oral glucose tolerance test. For 
rs7756992, we found that homozygous carriers of the risk allele had 
an estimated 22% lower CIR than the noncarriers (P = 3.5 × 10−9). By 
contrast, heterozygous carriers showed a very small (2%) and nonsig-
nificant (P = 0.23) reduction of CIR compared with noncarriers (Fig. 2). 
Testing the null hypothesis of no difference among all three genotypic 
states against the full model gave a P value of 2.5 × 10−8. Hence, the 
effect of the variant on CIR is highly significant and is close to recessive. 
This observation is consistent with the observed effect of the variant in 
disease risk (that is, the increased risk for the heterozygous carriers is 
very modest). Furthermore, the effect on CIR was present in both males 
and females (Fig. 2) and in individuals with T2D as well as controls, and 
adjusting for BMI status did not affect the results (Supplementary Table 
6 online). The effect of rs13266634 on insulin response was smaller but 
significant, and for this risk variant, the reduction in CIR was consistent 
with an additive effect. We did not observe any effect on insulin sensiti-
vity for either variant (Supplementary Table 6). For both variants, we 
obtained similar results by measuring insulin response in the form of 
the insulinogenic index (see Methods).
Based on our data from all five groups of European ancestry for 
TCF7L2, CDKAL1 and SLC30A8, we found that the TCF7L2 risk vari-
ant and the CDKAL1 risk variant were positively correlated within the 
populations with T2D (P = 0.0057). Given that both have apparently 
stronger effects for non-obese cases, this suggests that they might work 
through a similar pathway. However, further investigation is necessary 
to confirm and understand this apparent correlation. By contrast, the 
risk conferred by the SLC30A8 variant is consistent with its effects being 
multiplicative with the joint effects of TCF7L2 and CDKAL1.
Considering that our fast-tracking strategy is not expected to be com-
prehensive and that the susceptibility variants identified so far for T2D, 
including the variant in TCF7L2, explain only a small fraction of the 
familial clustering of the disease, it is expected that there are many more 
variants with effects similar to those in CDKAL1 and SLC30A8 that have 
yet to be identified. Still, the identification of CDKAL1 as a susceptibil-
ity gene for T2D adds a new piece to the puzzle of how genetic factors 
predispose to T2D. Although the function of this gene remains to be 
elucidated, we have shown that a variant within the gene is correlated 
with insulin secretion. The similarity to CDK5RAP1 further indicates 
that CDKAL1 may facilitate insulin production under glucotoxic condi-
tions through interaction with CDK5. In conclusion, we have identified 
a variant in CDKAL1 that predisposes to T2D and that blunts the insulin 
response in a nearly recessive manner.
METHODS
Icelandic study population. The Icelandic T2D group has been described previ-
ously11. A total of 1,500 individuals with T2D were recruited for this genome-
wide association study, which used the Infinium II assay method and the Sentrix 
HumanHap300 BeadChip (Illumina). Of these, 1,399 were successfully genotyped 
according to our quality control criteria and were used in the present case control-
analysis; 531 of the genotyped cases were obese (BMI ≥ 30), 700 were non-obese 
(BMI < 30) and information on BMI was missing for 168 cases. The controls 
used in this study consisted of 599 controls randomly selected from the Icelandic 
genealogical database and 4,676 individuals from other ongoing genome-wide 
association studies at deCODE. Specifically, approximately 1,400 of the controls 
came from studies on prostate cancer, and about 1,100 came from studies on 
breast cancer; studies on anxiety, addiction, schizophrenia and infectious diseases 
provided approximately 500 controls each. The study was approved by the Data 
Protection Commission of Iceland and the National Bioethics Committee of 
Iceland. Written informed consent was obtained from all affected individuals 
and controls.
Other study populations. The Danish female study group of 282 cases and 
629 controls, herein termed Denmark A, was selected from the Prospective 
Epidemiological Risk Factor (PERF) study in Denmark12. This is a group of 
postmenopausal women who took part in various placebo-controlled clinical 
trials and epidemiological studies at the Center for Clinical and Basic Research. 
In follow-up examinations of 5,847 women in 2000–2001, we collected medical 
histories (including type I or type II diabetes), family histories and informa-
tion on current or previous long-term use of drugs through personal interviews 
using a preformed questionnaire. If a subject was diagnosed with diabetes of 
either type I or type II, the date of diagnosis or treatment was also noted. The 
study was approved by the Ethical Committee of Copenhagen County and was 
in accordance with the principles of the Helsinki Declaration.
The second Danish study population (Denmark B) of 1,359 individuals with 
T2D and 4,858 controls with normal glucose tolerance was from the Steno 
Diabetes Center in Copenhagen (1,016 cases and 374 controls) and from the 
Inter99 population-based sample of 30- to 60-year-old individuals living in the 
greater Copenhagen area, sampled at Research Centre for Prevention and Health 
(343 affected individuals and 4,484 controls)13. Diabetes and pre-diabetes were 
diagnosed according to the 1999 World Health Organization (WHO) criteria. An 
oral glucose tolerance test was performed on participants in the Inter99 study 
as described13. Informed written consent was obtained from all subjects before 
participation. The study was approved by the Ethical Committee of Copenhagen 
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Figure 2  Association of rs7756992 and rs13266634 with insulin secretion. 
Mean log-transformed insulin secretion levels, estimated by corrected 
insulin response (CIR; see Methods), for the three different genotypes of 
the two SNPs, rs7756992 and rs13266634. Results are shown for 3,982 
individuals (231 T2D cases and 3,751 controls) from the Danish Inter99 
study that had an oral glucose tolerance test. Results are shown for all 
individuals and for males and females separately. The number of individuals 
analyzed for each genotype is shown in parentheses under each column, and 
the s.e.m. is indicated by vertical bars. P values are from a two–degree of 
freedom F test of the null model of no difference among the three genotype 
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The Philadelphia study population consisted of 468 individuals with T2D and 
1,024 control individuals. The study population was selected from the PENN 
CATH study, a cross-sectional study of the association of biochemical and genetic 
factors with coronary atherosclerosis in a study population of consecutive indi-
viduals undergoing cardiac catheterization at the University of Pennsylvania 
Medical Center. T2D was defined as a history of fasting blood glucose ≥ 126 mg 
dl–1, 2 h postprandial glucose ≥ 200 mg dl–1, use of oral hypoglycemic agents 
or use of insulin and oral hypoglycemic agents in a subject older than 40 years. 
The University of Pennsylvania Institutional Review Board approved the study 
protocol, and all subjects gave written informed consent. All affected individuals 
and controls were of European ancestry. Ethnicity was determined through self-
report and has been validated by genotyping of ethnicity markers14.
The Dutch Breda study population consisted of 370 T2D affected individuals 
and 916 control individuals. The affected individuals were recruited in 1998–1999 
in collaboration with the Diabetes Service Breda and 80 general practitioners 
from the region around Breda. All patients were diagnosed according to WHO 
criteria (plasma glucose levels >11.1 mmol l–1 or fasting plasma glucose levels 
≥7.0 mmol l–1) and underwent clinical and laboratory evaluations for their diabe-
tes at regular 3-month intervals. The Medical Ethics Committee of the University 
Medical Centre in Utrecht approved the study protocol. All probands gave written 
informed consent and filled out a questionnaire on clinical data, including any 
diabetes-related medication as well as height and weight at present and at the age 
of 20. The controls were healthy Dutch blood bank donors of European origin.
All subjects in the Hong Kong study population were of southern Han Chinese 
ancestry and resided in Hong Kong. The cases consisted of 1,500 individuals with 
T2D selected from the Prince of Wales Hospital Diabetes Registry15. Of these, 682 
had young-onset diabetes (age at diagnosis ≤ 40 years) with a positive family his-
tory. An additional 818 cases were randomly selected from the same registry. The 
controls consisted of 1,000 subjects with normal glucose tolerance (fasting plasma 
glucose < 6.1 mmol l–1). Of these, 617 were recruited from members of the general 
population participating in a community-based cardiovascular risk screening pro-
gram as well as from hospital staff. In addition, 383 subjects were recruited from 
a cardiovascular risk screening program for adolescents. Informed consent was 
obtained for each participating subject. This study was approved by the Clinical 
Research Ethics Committee of the Chinese University of Hong Kong.
The African study population comes from the Africa America Diabetes 
Mellitus study, which was originally designed as an affected sibling pair study 
with enrollment of available spouses as controls. It has since been expanded to 
include other family members of the affected pairs and population controls. 
Recruitment strategies and eligibility criteria for the families enrolled in this 
report have been described previously16. This West African case-control series 
consisted of individuals from the Yoruba (233 affected individuals, 432 controls) 
and Igbo (237 affected individuals, 276 controls) groups from Nigeria, and from 
the Akan (257 affected individuals, 248 controls), Ewe (22 affected individuals, 
30 controls) and Gaa-Adangbe (123 affected individuals, 141 controls) groups 
from Ghana. Further characteristics of the seven case-control groups used in this 
study are shown in Supplementary Table 7 online.
The DNA used for genotyping in all replication study populations was 
the product of whole-genome amplification (GenomiPhi Amplification kit, 
Amersham) of DNA isolated from the peripheral blood.
Illumina genome-wide genotyping. All Icelandic case and control samples 
were assayed with the Infinium HumanHap300 SNP chips (Illumina), contain-
ing 317,503 tagging SNPs derived from phase I of the International HapMap 
project. Of the SNPs assayed on the chip, 4,324 SNPs were excluded because 
they showed either (i) a call rate lower than 95% in cases or controls; (ii) a minor 
allele frequency <1% in the population or (iii) significant distortion from Hardy-
Weinberg equilibrium in the controls (P < 0.001). Any samples with yield <98% 
were excluded from the analysis. Thus, the final analyses presented in the text 
use 313,179 SNPs.
Single-SNP genotyping. All single-SNP genotyping was carried out at deCODE 
Genetics on the Centaurus (Nanogen) platform17. The quality of each Centaurus 
SNP assay was evaluated by genotyping each assay in the CEU and/or YRI 
HapMap samples and comparing the results with the HapMap data. Assays with 
a mismatch rate >1.5% were not used, and a linkage disequilibrium (LD) test 
was used for markers known to be in LD.
Association analysis. For association analysis, we used standard likelihood ratio 
statistics, implemented in NEMO software18, to calculate two-sided P values and 
allele-specific ORs for each individual allele, assuming a multiplicative model 
(that is, that the two alleles are independent, or in Hardy-Weinberg-Equilibrium, 
within the population of affected individuals). This corresponds to a setting 
where the ratio of the risks for homozygous carriers (AA) and heterozygous 
carriers (Aa) is the same as the ratio of the risks for heterozygous carriers and 
noncarriers, or (risk(AA) / risk(Aa)) = (risk(Aa) / risk(aa)). Allelic frequencies, 
rather than carrier frequencies, are presented for the markers, and P values are 
given after adjustment for the relatedness of the subjects. When estimating geno-
type-specific OR (Table 2), we estimated genotype frequencies in the control 
population assuming HWE after checking that the data were not inconsistent 
with this assumption.
In general, allele and haplotype frequencies were estimated by maximum 
likelihood, and tests of differences between cases and controls were performed 
using a generalized likelihood ratio test19. This method is particularly useful in 
situations where there are some missing genotypes for the marker of interest, 
and genotypes of another marker that is in strong LD with the marker of interest 
are used to provide some partial information. This was used in the association 
tests presented in Supplementary Table 4 to ensure that the comparison of the 
highly correlated markers was done using the same number of individuals. To 
handle uncertainties with phase and missing genotypes, maximum likelihood 
estimates, likelihood ratios and P values are computed directly for the observed 
data, and hence the loss of information owing to uncertainty in phase and missing 
genotypes is automatically captured by the likelihood ratios.
Results from multiple case-control groups were combined using a Mantel-
Haenszel model20 in which the groups were allowed to have different population 
frequencies for alleles and for genotypes but were assumed to have common 
relative risks.
For both the CDKAL1 and SLC30A8 variants (rs7756992 and rs13266634), we 
did not detect any significant differences in frequencies among the disease groups 
(see description of the Icelandic study population) that make up the Icelandic 
genome-wide control sets (P = 0.13 and 0.19, respectively).
Correction for relatedness of the subjects and genomic control. Some of the 
individuals in both the affected and control Icelandic groups are related to each 
other, causing the χ2 test statistic to have a mean >1 and median >0.6752. We 
estimated the inflation factor by calculating the average of the 653,025 χ2 statis-
tics, which was a method of genomic control5 to adjust for both relatedness and 
potential population stratification. The inflation factors were estimated as 1.287 
for all affected individuals, 1.204 for non-obese affected individuals and 1.184 
for obese affected individuals. In addition to estimating the correction factors 
for the test statistics using the method of genomic control, we also applied a 
simulation method where genotypes are simulated through the genealogy of 
708,683 Icelanders21. Specifically, the simulation procedure estimates the cor-
rection factor that is required owing to the known relatedness among the study 
participants. Based on 100,000 simulated data sets, the estimates were 1.211 for all 
affected individuals, 1.157 for non-obese affected individuals and 1.136 for obese 
affected individuals. We were not surprised that the correction factors estimated 
based on genomic control were somewhat larger than those based on simulations 
through genealogy, but it is comforting to us that the differences were not very 
substantial. This comparison shows that most of the adjustment was due to the 
relatedness of the participants; however, the higher estimates from the genomic 
controls indicate that there is some additional correction (possibly owing to 
genotyping quality, missing data or population stratification that, although small, 
is detectable in the Icelandic population)22. We do feel that the estimates based 
on genomic control, when available, are the most appropriate and conservative, 
and hence we have used that in the presentation in the paper.
Quantitative analysis. Data from oral glucose tolerance tests on individuals from 
the Danish Inter99 study were used to calculate insulin secretion as corrected 
insulin response (CIR) using the following equation: (100 × insulin at 30 min) / 
(glucose at 30 min × (glucose at 30 min – 3.89 mmol))23,24. Insulin sensitivity 
was estimated as the reciprocal of the insulin resistance according to the homeo-
stasis model assessment (HOMA): 22.5 / (fasting insulin × fasting glucose)25. 
The association between CIR (HOMA) and genotype status was tested using 
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response variable. For the full model, the two explanatory variables were the 
indicator variables for the heterozygous carriers and the homozygous carriers 
so that the fitted coefficients corresponded to the estimated effects for each of 
the two genotypic states relative to the noncarriers. Apart from estimated effects, 
standard errors and P values calculated for each of the two explanatory variables 
separately, a two–degree of freedom P value based on an F-test was calculated to 
test the null model (no difference among all three genotypic states) against the 
full model (Supplementary Table 6). We adjusted for sex, age and affection status 
by including the appropriate terms as explanatory variables. For comparison, 
insulin secretion was also calculated in the form of the insulinogenic index24
(insulin at 30 min – insulin at 0 min) / (glucose at 30 min – glucose at 0 min), 
yielding comparable results.
Requests for materials: kstefans@decode.is or vstein@decode.is
Note: Supplementary information is available on the Nature Genetics website.
ACKNOWLEDGMENTS
We thank the individuals with T2D and other study participants whose 
contribution made this work possible. We also thank the nurses at Noatun 
(deCODE’s sample recruitment center) and personnel at the deCODE core 
facilities for their hard work and enthusiasm. The Denmark B studies were 
supported by a grant from Eugene 2. Support for the Africa America Diabetes 
Mellitus (AADM) study is provided by the US National Institutes of Health, 
including the National Center on Minority Health and Health Disparities 
(3T37TW00041-03S2), the National Institute of Diabetes and Digestive and Kidney 
Diseases (DK072128), the National Human Genome Research Institute and the 
National Center for Research Resources (RR03048). The Hong Kong Diabetes 
case-control study was supported by the Hong Kong Research Grants Committee 
Central Allocation Scheme CUHK 1/04C.
COMPETING INTERESTS STATEMENT
The authors declare competing financial interests: details accompany the full-text 
HTML version of the paper at http://www.nature.com/naturegenetics.
Published online at http://www.nature.com/naturegenetics
Reprints and permissions information is available online at http://npg.nature.com/
reprintsandpermissions
1. Sladek, R. et al. A genome-wide association study identifies novel risk loci for type 2 
diabetes. Nature 445, 881–885 (2007).
2. Grant, S.F. et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of 
type 2 diabetes. Nat. Genet. 38, 320–323 (2006).
3. Helgason, A. et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes 
and adaptive evolution. Nat. Genet. 39, 218–225 (2007).
4. Pe’er, I. et al. Evaluating and improving power in whole-genome association studies 
using fixed marker sets. Nat. Genet. 38, 663–667 (2006).
5. Devlin, B. & Roeder, K. Genomic control for association studies. Biometrics 55, 997–
1004 (1999).
6. Skol, A.D., Scott, L.J., Abecasis, G.R. & Boehnke, M. Joint analysis is more efficient 
than replication-based analysis for two-stage genome-wide association studies. Nat. 
Genet. 38, 209–213 (2006).
7. Chimienti, F., Devergnas, S., Favier, A. & Seve, M. Identification and cloning of a beta-
cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes
53, 2330–2337 (2004).
8. Ching, Y.P., Pang, A.S., Lam, W.H., Qi, R.Z. & Wang, J.H. Identification of a neuronal 
Cdk5 activator-binding protein as Cdk5 inhibitor. J. Biol. Chem. 277, 15237–15240 
(2002).
9. Wei, F.Y. et al. Cdk5-dependent regulation of glucose-stimulated insulin secretion. Nat. 
Med. 11, 1104–1108 (2005).
10. Ubeda, M., Rukstalis, J.M. & Habener, J.F. Inhibition of cyclin-dependent kinase 5 
activity protects pancreatic beta cells from glucotoxicity. J. Biol. Chem. 281, 28858–
28864 (2006).
11. Reynisdottir, I. et al. Localization of a susceptibility gene for type 2 diabetes to chromo-
some 5q34-q35.2. Am. J. Hum. Genet. 73, 323–335 (2003).
12. Tanko, L.B., Bagger, Y.Z., Nielsen, S.B. & Christiansen, C. Does serum cholesterol 
contribute to vertebral bone loss in postmenopausal women? Bone 32, 8–14 (2003).
13. Jorgensen, T. et al. A randomized non-pharmacological intervention study for prevention 
of ischaemic heart disease: baseline results Inter99. Eur. J. Cardiovasc. Prev. Rehabil.
10, 377–386 (2003).
14. Helgadottir, A. et al. A variant of the gene encoding leukotriene A4 hydrolase confers 
ethnicity-specific risk of myocardial infarction. Nat. Genet. 38, 68–74 (2006).
15. Yang, X. et al. Development and validation of stroke risk equation for Hong Kong 
Chinese patients with type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 
Care 30, 65–70 (2007).
16. Rotimi, C.N. et al. In search of susceptibility genes for type 2 diabetes in West Africa: 
the design and results of the first phase of the AADM study. Ann. Epidemiol. 11, 51–58 
(2001).
17. Kutyavin, I.V. et al. A novel endonuclease IV post-PCR genotyping system. Nucleic 
Acids Res. 34, e128 (2006).
18. Gretarsdottir, S. et al. The gene encoding phosphodiesterase 4D confers risk of ischemic 
stroke. Nat. Genet. 35, 131–138 (2003).
19. Rice, J.A. Mathematical Statistics and Data Analysis (Wadsworth, Belmont, California, 
1995).
20. Mantel, N. & Haenszel, W. Statistical aspects of the analysis of data from retrospective 
studies of disease. J. Natl. Cancer Inst. 22, 719–748 (1959).
21. Stefansson, H. et al. A common inversion under selection in Europeans. Nat. Genet.
37, 129–137 (2005).
22. Helgason, A., Yngvadottir, B., Hrafnkelsson, B., Gulcher, J. & Stefansson, K. An 
Icelandic example of the impact of population structure on association studies. Nat. 
Genet. 37, 90–95 (2005).
23. Sluiter, W.J., Erkelens, D.W., Reitsma, W.D. & Doorenbos, H. Glucose tolerance and 
insulin release, a mathematical approach I. Assay of the beta-cell response after oral 
glucose loading. Diabetes 25, 241–244 (1976).
24. Hanson, R.L. et al. Evaluation of simple indices of insulin sensitivity and insulin secre-
tion for use in epidemiologic studies. Am. J. Epidemiol. 151, 190–198 (2000).
25. Matthews, D.R. et al. Homeostasis model assessment: insulin resistance and beta-cell 
function from fasting plasma glucose and insulin concentrations in man. Diabetologia
28, 412–419 (1985).
26. The International HapMap Consortium. A haplotype map of the human genome. Nature
437, 1299–1320 (2005).
©
20
07
 
N
at
ur
e 
Pu
bl
is
hi
ng
 G
ro
u
p 
 h
ttp
://
w
w
w.
n
at
ur
e.
co
m
/n
at
ur
eg
en
et
ic
s
